Cargando…
Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a novel beta coronavirus. SARS-CoV-2 uses spike glycoprotein to interact with host angiotensin-converting enzyme 2 (ACE2) and ensure cell recognition. High infectivity of SARS-CoV-2 rai...
Autores principales: | Shah, Masaud, Ahmad, Bilal, Choi, Sangdun, Woo, Hyun Goo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657873/ https://www.ncbi.nlm.nih.gov/pubmed/33200028 http://dx.doi.org/10.1016/j.csbj.2020.11.002 |
Ejemplares similares
-
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Passariello, Margherita, et al.
Publicado: (2021) -
The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs
por: Shah, Masaud, et al.
Publicado: (2022) -
Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction
por: Shah, Masaud, et al.
Publicado: (2023) -
Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses (SARS‐CoV‐1 and SARS‐CoV‐2)
por: Rombel‐Bryzek, Agnieszka, et al.
Publicado: (2022) -
SARS-CoV-2 spike binding to ACE2 is stronger and longer ranged with glycans
por: Huang, Yihan, et al.
Publicado: (2022)